Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Br J Dermatol 2024;190:477–85 Doi: 10.1093/bjd/ljad429.
No new safety signals were found in the three-year safety data on bimekizumab for plaque PsO. Additionally, incidence of oral candidiasis significantly decreased with each subsequent year.